Healthcare / BiotechnologyNasdaqCM
$7.47
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-180000.00 · quality 29.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$725M
P/E
N/A
•EV/EBITDA
N/A
•ROE
9.3%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+10.1%
FCF CAGR
—
FCF margin
-0.2%
FCF / Net income
-0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $116.6M · net income $9.9M · FCF $-180000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $116.6M | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M | $20.9M | — | $6000.00 | $1.0M | — | — | $275000.00 | $3.6M | $57.9M | $97.6M | $85.7M | $25.1M |
| Net Income | $9.9M | $9.9M | $17.9M | $-85.5M | $4.3M | $-87.9M | $-56.2M | $-55.2M | $-30.1M | $-21.6M | $-16.9M | $-14.8M | $-6.6M | $-10.0M | $-7.0M | $-8.5M | $10.9M | $-39.4M |
| EBITDA | $14.0M | $14.0M | $17.7M | $-66.2M | $10.3M | $-87.6M | $-57.2M | $-57.1M | $-33.7M | $-21.6M | $-20.0M | $-13.3M | $-6.8M | $-9.1M | $-5.9M | $-7.3M | $15.1M | $-38.5M |
| EPS | 0.02 | 0.02 | 0.05 | -1.41 | 0.03 | -2.87 | — | — | — | — | — | — | — | — | -0.21 | -0.27 | 0.36 | -1.54 |
| Gross Margin | — | — | 96.3% | 95.9% | 95.3% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 9.9% | 9.9% | 15.3% | -59.3% | 9.0% | -1197.8% | -273.9% | — | -563700.0% | -2143.6% | — | — | -2730.5% | -278.9% | -14.1% | -10.0% | 15.3% | -160.9% |
| Net Margin | 8.5% | 8.5% | 16.9% | -75.3% | 4.2% | -1198.3% | -268.5% | — | -500916.7% | -2118.0% | — | — | -2404.7% | -274.6% | -12.1% | -8.7% | 12.7% | -157.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 | -0.00 | -0.01 | 0.01 | 0.01 | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-180000.00 | $-180000.00 | $-6.0M | $17.4M | $5.7M | $-84.6M | — | $-43.7M | $-28.9M | $-20.0M | — | — | — | $-40.7M | $-64.6M | $-85.1M | $135.0M | $-24.5M |
| Returns | ||||||||||||||||||
| ROE | 9.3% | 9.3% | 28.3% | 540.1% | 10.1% | -214.0% | -73.9% | -80.7% | -25.1% | -70.1% | -105.4% | -47.0% | 6.0% | 9.7% | 7.5% | -4.9% | 11.9% | -57.1% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 10.2% | 10.2% | -6.8% | 10.9% | 1294.0% | -65.0% | — | — | -99.4% | — | — | — | -92.4% | -93.7% | -40.7% | 13.9% | 242.0% | — |
| EPS Growth | -60.0% | -60.0% | 103.5% | -4800.0% | 101.0% | — | — | — | — | — | — | — | — | — | 22.2% | -175.0% | 123.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
221.2%
EPS terminal req.
$0.66
Spread vs growth
-281.2%
5Y implied EPS CAGR
109.2%
EPS terminal req.
$0.80
Spread vs growth
-169.2%
10Y implied EPS CAGR
51.7%
EPS terminal req.
$1.29
Spread vs growth
-111.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.